End-of-day quote
Shenzhen S.E.
03:30:00 06/05/2024 am IST
|
5-day change
|
1st Jan Change
|
8.79
CNY
|
+8.52%
|
|
+11.97%
|
-19.28%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,025
|
2,225
|
2,426
|
2,967
|
2,650
|
3,639
|
Enterprise Value (EV)
1 |
1,839
|
1,684
|
1,816
|
2,416
|
2,277
|
3,266
|
P/E ratio
|
28.9
x
|
10.6
x
|
27.1
x
|
38.6
x
|
34.5
x
|
45.4
x
|
Yield
|
0.5%
|
0.9%
|
0.96%
|
0.68%
|
0.76%
|
0.55%
|
Capitalization / Revenue
|
0.71
x
|
0.69
x
|
0.71
x
|
0.82
x
|
0.64
x
|
0.89
x
|
EV / Revenue
|
0.64
x
|
0.52
x
|
0.53
x
|
0.67
x
|
0.55
x
|
0.8
x
|
EV / EBITDA
|
14.6
x
|
12.8
x
|
13.4
x
|
18.4
x
|
15.4
x
|
20.9
x
|
EV / FCF
|
-39.6
x
|
33.4
x
|
17
x
|
-194
x
|
-17
x
|
-31.2
x
|
FCF Yield
|
-2.53%
|
3%
|
5.87%
|
-0.52%
|
-5.88%
|
-3.21%
|
Price to Book
|
1.42
x
|
1.32
x
|
1.39
x
|
1.6
x
|
1.38
x
|
1.84
x
|
Nbr of stocks (in thousands)
|
3,34,123
|
3,34,123
|
3,34,123
|
3,34,123
|
3,34,123
|
3,34,123
|
Reference price
2 |
6.060
|
6.660
|
7.260
|
8.880
|
7.930
|
10.89
|
Announcement Date
|
22/03/19
|
14/04/20
|
26/03/21
|
08/04/22
|
21/04/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2,858
|
3,243
|
3,440
|
3,612
|
4,145
|
4,106
|
EBITDA
1 |
126
|
132
|
135.3
|
131.1
|
147.5
|
156
|
EBIT
1 |
69.91
|
79.06
|
81.46
|
75.59
|
88.94
|
94.3
|
Operating Margin
|
2.45%
|
2.44%
|
2.37%
|
2.09%
|
2.15%
|
2.3%
|
Earnings before Tax (EBT)
1 |
85.26
|
257.1
|
114.5
|
102.7
|
102.5
|
110.2
|
Net income
1 |
70.88
|
211.6
|
89.39
|
77.3
|
77.83
|
81.64
|
Net margin
|
2.48%
|
6.52%
|
2.6%
|
2.14%
|
1.88%
|
1.99%
|
EPS
2 |
0.2100
|
0.6300
|
0.2675
|
0.2300
|
0.2300
|
0.2400
|
Free Cash Flow
1 |
-46.47
|
50.49
|
106.6
|
-12.45
|
-134
|
-104.8
|
FCF margin
|
-1.63%
|
1.56%
|
3.1%
|
-0.34%
|
-3.23%
|
-2.55%
|
FCF Conversion (EBITDA)
|
-
|
38.24%
|
78.81%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
23.87%
|
119.24%
|
-
|
-
|
-
|
Dividend per Share
2 |
0.0300
|
0.0600
|
0.0700
|
0.0600
|
0.0600
|
0.0600
|
Announcement Date
|
22/03/19
|
14/04/20
|
26/03/21
|
08/04/22
|
21/04/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
186
|
541
|
610
|
551
|
372
|
373
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-46.5
|
50.5
|
107
|
-12.4
|
-134
|
-105
|
ROE (net income / shareholders' equity)
|
5.07%
|
13.6%
|
5.35%
|
4.43%
|
4.29%
|
4.31%
|
ROA (Net income/ Total Assets)
|
2.09%
|
2.1%
|
1.93%
|
1.66%
|
1.79%
|
1.91%
|
Assets
1 |
3,384
|
10,082
|
4,644
|
4,653
|
4,352
|
4,273
|
Book Value Per Share
2 |
4.260
|
5.060
|
5.210
|
5.550
|
5.750
|
5.910
|
Cash Flow per Share
2 |
0.6500
|
0.8700
|
1.530
|
1.240
|
1.360
|
1.370
|
Capex
1 |
48.9
|
87.5
|
42.2
|
71.2
|
104
|
194
|
Capex / Sales
|
1.71%
|
2.7%
|
1.23%
|
1.97%
|
2.51%
|
4.73%
|
Announcement Date
|
22/03/19
|
14/04/20
|
26/03/21
|
08/04/22
|
21/04/23
|
21/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -19.28% | 408M | | +15.21% | 70.09B | | -2.19% | 24.01B | | +8.13% | 8.32B | | -18.28% | 8.23B | | 0.00% | 8.08B | | +19.12% | 4.41B | | 0.00% | 4.12B | | -2.96% | 3.88B | | +23.97% | 3.71B |
Pharmaceuticals Wholesale
|